Centene Faces HBR Pressures: Will Scale Support Stability?

25.08.25 18:35 Uhr

Werte in diesem Artikel
Aktien

29,95 EUR 0,53 EUR 1,80%

Indizes

6.643,7 PKT 39,0 PKT 0,59%

935,5 PKT -8,9 PKT -0,94%

Centene Corporation CNC relies on its Health Benefit Ratio (HBR) as a measure of profitability. Because Medicaid and ACA marketplace plans generate thinner margins than commercial insurance, even modest increases in HBR can meaningfully pressure earnings. As a dominant player in both markets, Centene remains highly sensitive to these shifts.Recently, several factors have strained HBR. Rising utilization in outpatient and behavioral health services, escalating specialty drug expenses, and the return of deferred care have all increased medical costs. At the same time, Medicaid redeterminations are shifting enrollment toward higher-acuity members, driving up claims severity. In second-quarter 2025, Centene’s HBR rose 550 basis points, reflecting lower Marketplace risk adjustment transfers, higher medical costs across Medicaid and Marketplace, and a Medicare Advantage premium deficiency reserve.To counter these headwinds, Centene is strengthening utilization management, expanding value-based care contracts, tightening pharmacy cost controls, and pursuing digital efficiency investments. Streamlining through divestitures further supports operational discipline.The newly enacted One Big Beautiful Bill Act adds structural challenges. Cuts to Medicaid funding, stricter verification requirements, and ACA enrollment curbs threaten to reduce membership, increase administrative costs, and cap premium growth potential.Looking forward, balancing medical cost containment with careful enrollment management prudently will drive profitability. Despite near-term margin pressures, its scale, government program expertise, and ongoing efficiency measures provide resilience. Over the long term, these strengths should enable Centene to stabilize operations and maintain its leadership position in managed care.What About its Peers?HBR at UnitedHealth Group UNH and Humana HUM, two other healthcare plan providers, are influenced by medical cost trends, service utilization, and pharmacy spending. By effectively managing these elements, UnitedHealth as well as Humana maintains stable HBR levels that drive profitability. Leveraging technology, value-based care models, care coordination, and scale, UnitedHealth and Humana ensure margin strength and reinforce their leadership as sustainable healthcare providers.CNC’s Price PerformanceShares of CNC have lost 51.5% year to date, underperforming the industry.Image Source: Zacks Investment ResearchCNC’s Cheap ValuationCNC trades at a forward 12-month price-to-earnings of 11.55, below the industry average of 14.96.Image Source: Zacks Investment ResearchEstimate Movements for CNCThe Zacks Consensus Estimate for CNC’s third-quarter and fourth-quarter 2025 EPS witnessed a southward revision over the past seven days. The consensus estimate for full-year 2025 and 2026 EPS also followed suit. Image Source: Zacks Investment ResearchThe consensus estimate for CNC’s 2025 revenues indicates a year-over-year increase, but the same for EPS suggests a decline. For 2026, the case is exactly the opposite.CNC stock currently carries a Zacks Rank #5 (Strong Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Centene

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Centene Corp.

Wer­bung

Analysen zu Centene Corp.

DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
15.06.2015Centene HoldDeutsche Bank AG
15.06.2015Centene Mkt PerformFBR Capital
28.04.2015Centene Mkt PerformFBR Capital
11.02.2015Centene NeutralUBS AG
15.12.2014Centene HoldDeutsche Bank AG
DatumRatingAnalyst
05.12.2006Update Centene Corp.: SellGoldman Sachs
12.06.2006Update Centene Corp.: SellMatrix Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen